Product Information
APIDRA 100 UNIT/ML VIAL is a brand product labeled by Sanofi-Aventis U.S. LLC, priced at $8.1623 per ML under NDC 00088250033. Its NADAC has been published 671 times since Nov 28, 2013.
Strength
100 [iU]/mL
Manufacturer
Sanofi-Aventis U.S. LLCNDC
00088250033
Classification
Brand
Dosage Form
INJECTION, SOLUTION
Route
INTRAVENOUS; SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
INSULIN GLULISINEApproval Type
Biologic (BLA)
FDA Application
BLA021629On Market Since
2/24/2009
Pharmacological Classes
Price Statistics
The NADAC for APIDRA 100 UNIT/ML VIAL has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 39.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $8.1623 per ML |
|---|---|
| All-time high | $27.2795 (Oct 16, 2019) |
| All-time low | $8.1606 (Aug 19, 2026) |
| 52-week high | $8.1767 |
| 52-week low | $8.1606 |
| Median price | $24.5424 |
| Average price | $21.0872 |
| Largest weekly change | -70.0% (Jan 3, 2024) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Sanofi-Aventis U.S. LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
insulin glulisine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Insulin Analog class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of APIDRA 100 UNIT/ML VIAL?
The current National Average Drug Acquisition Cost (NADAC) for APIDRA 100 UNIT/ML VIAL, manufactured by Sanofi-Aventis U.S. LLC, is $8.1623 per ML (NDC 00088250033), effective Sep 30, 2026.
How has the price of APIDRA 100 UNIT/ML VIAL changed over time?
Over the history we have for it, the NADAC for APIDRA 100 UNIT/ML VIAL has declined 39.5%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for APIDRA 100 UNIT/ML VIAL?
Since Nov 28, 2013, the NADAC for APIDRA 100 UNIT/ML VIAL has ranged from a low of $8.1606 (Aug 19, 2026) to a high of $27.2795 (Oct 16, 2019), with a median of $24.5424 per ML.
Are there cheaper alternatives to APIDRA 100 UNIT/ML VIAL?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as APIDRA 100 UNIT/ML VIAL in a comparable dosage form, but none are currently priced below it.
Who manufactures APIDRA 100 UNIT/ML VIAL?
APIDRA 100 UNIT/ML VIAL (NDC 00088250033) is labeled by Sanofi-Aventis U.S. LLC, and CMS classifies it as a brand product.